SEBI confirms interim order halting Par Drugs' slump sale to a promoter entity, citing undervaluation and disclosure lapses.
Independent valuation ordered after SEBI found the proposed sale undervalued the business and lacked fairness opinion.
The confirmatory order maintains a freeze on the transaction pending a full investigation into the deal.